Xeris Biopharma Holdings, Inc. Common Stock XERS
$8.60
+3.24%
at last close
Analyst Consensus
- Consensus Rating
- Buy (4 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $10.80
- Implied Upside
- +25.6%
- Price Target Range
- $8.00 – $18.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-03-02 | HC Wainwright & Co.Brandon Folkes |
Reiterates | Buy | $10 |
| 2026-01-09 | HC Wainwright & Co.Brandon Folkes |
Reiterates | Buy | $10 |
| 2025-12-09 | BarclaysGlen Santangelo |
Initiates coverage on | Overweight | $9 |
| 2025-11-07 | OppenheimerLeland Gershell |
Maintains | Outperform | $18 |
| 2025-11-07 | HC Wainwright & Co.Brandon Folkes |
Maintains | Buy | $10 |
| 2025-11-07 | Piper SandlerDavid Amsellem |
Maintains | Neutral | $6 → $8 |
| 2025-10-29 | OppenheimerLeland Gershell |
Maintains | Outperform | $8 → $18 |
| 2025-08-19 | Leerink PartnersRoanna Ruiz |
Maintains | Outperform | $7 → $9 |
| 2025-08-12 | HC Wainwright & Co.Brandon Folkes |
Assumes | Buy | $10 |
| 2025-08-08 | Craig-HallumChase Knickerbocker |
Maintains | Buy | $7 → $11 |
| 2025-08-08 | OppenheimerLeland Gershell |
Maintains | Outperform | $7 → $8 |
| 2025-05-09 | OppenheimerLeland Gershell |
Maintains | Outperform | $6 → $7 |
| 2025-03-07 | Leerink PartnersRoanna Ruiz |
Maintains | Outperform | $5 → $6 |
| 2025-03-07 | Craig-HallumChase Knickerbocker |
Maintains | Buy | $5 → $7 |
| 2025-03-07 | Piper SandlerDavid Amsellem |
Reiterates | Neutral | $3 → $4 |
| 2025-03-07 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $7 → $8 |
| 2025-01-29 | JefferiesGlen Santangelo |
Reiterates | Buy | $4 → $6 |
| 2024-11-11 | HC Wainwright & Co.Oren Livnat |
Maintains | Buy | $6 → $7 |
| 2024-11-11 | Piper SandlerDavid Amsellem |
Downgrades | Overweight → Neutral | $3 |
| 2024-08-15 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $6 |
| 2024-05-31 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $6 |
| 2024-05-10 | Piper SandlerDavid Amsellem |
Reiterates | Overweight | $4 → $3 |
| 2024-03-28 | OppenheimerLeland Gershell |
Initiates coverage on | Outperform | $5 |
| 2024-03-07 | HC Wainwright & Co.Oren Livnat |
Maintains | Buy | $6 → $6 |
| 2023-11-13 | HC Wainwright & Co.Oren Livnat |
Maintains | Buy | $6 → $6 |
| 2023-11-10 | Piper SandlerDavid Amsellem |
Maintains | Overweight | $5 → $4 |
| 2023-08-28 | Craig-HallumRobin Garner |
Initiates coverage on | Buy | $5 |
| 2023-08-09 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $6 |
| 2023-05-10 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $6 |
| 2023-03-09 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $6 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $8.60
- Market Cap
- $1.57 billion
- 52-Week Range
- $4.87 – $10.08
- Average Volume
- 1.78 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.